NCT02220335 (PADN-5) is a NA clinical trial of Pulmonary arterial denervation in Pulmonary Hypertension, sponsored by Nanjing First Hospital, Nanjing Medical University.

Who is sponsoring NCT02220335?

NCT02220335 is sponsored by Nanjing First Hospital, Nanjing Medical University.

What drugs are being tested in NCT02220335?

Interventions in NCT02220335: Pulmonary arterial denervation, Standard treatment.

What condition does NCT02220335 study?

NCT02220335 studies Pulmonary Hypertension.

Is NCT02220335 still recruiting?

NCT02220335 is currently completed. Last updated 30 July 2019.

Last reviewed 2019-07-30 · How we verify

NCT02220335: PADN-5

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure

Completed NA Last updated 30 July 2019

What this trial tests

NA trial testing Pulmonary arterial denervation in Pulmonary Hypertension in 98 participants. Completed in 30 December 2018.

Timeline

8 August 2014

Primary endpoint
16 June 2018

30 December 2018

Quick facts

Lead sponsor	Nanjing First Hospital, Nanjing Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	98
Start date	8 August 2014
Primary completion	16 June 2018
Estimated completion	30 December 2018
Sites	1 location across China

Drugs / interventions tested

Pulmonary arterial denervation
Standard treatment

Conditions studied

Pulmonary Hypertension — all drugs for Pulmonary Hypertension →

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

18 and older, any sex, with Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A number of 100 patients with pulmonary hypertension associated with the left Heart failure scheduled for elective pulmonary arterial denervation (PADN) are randomized 1:1 to either PADN or control group.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Autonomic nervous system involvement in pulmonary arterial hypertension.
Vaillancourt M, Chia P, Sarji S, Nguyen J, et al · · 2017 · cited 76× · PMID 29202826 · DOI 10.1186/s12931-017-0679-6
Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension Associated With Left Heart Failure: The PADN-5 Study.
Zhang H, Zhang J, Chen M, Xie DJ, et al · · 2019 · cited 74× · PMID 30732732 · DOI 10.1016/j.jcin.2018.09.021
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.
Ameri P, Mercurio V, Pollesello P, Anker MS, et al · · 2024 · cited 12× · PMID 38639017 · DOI 10.1002/ejhf.3236
3-Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension: Results From PADN-5 Trial.
Zhang H, Kan J, Zhang J, Xie D, et al · · 2023 · cited 9× · PMID 37354146 · DOI 10.1016/j.jchf.2023.05.016
Future Perspectives of Pulmonary Hypertension Treatment.
Hsu CH, Huang WC, Chang WT. · · 2022 · cited 8× · PMID 35873130 · DOI 10.6515/acs.202207_38(4).20220331a
Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.
Corboz MR, Nguyen TL, Stautberg A, Cipolla D, et al · · 2024 · cited 6× · PMID 39388691 · DOI 10.1089/jamp.2024.0016
Flipping the focus - treating post-capillary pulmonary hypertension with pulmonary artery denervation.
Hart JP, Davies MG. · · 2026 · PMID 41835995 · DOI 10.4244/aij-d-26-00006

Verify or expand the search:

Other recruiting trials for Pulmonary Hypertension

Currently open trials in the same condition.

NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
NCT07073820 — A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P · Phase 2 · recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
NCT07187206 — Safety and Efficacy of FETO in CDH Phase III · Phase 3 · recruiting
NCT07206173 — Londrina Activities of Daily Living Protocol in Pulmonary Hypertension · recruiting

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02220335 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
Last refreshed: 30 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02220335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing